SCHEMBL5136200

SCHEMBL5136200

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(OC)cc1)Cc1ccc(F)c(Br)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.43
NPSR1 Q6W5P4 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
TSHR P16473 4/20 0.36
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 3/20 0.36
GAA P10253 2/20 0.36
LMNA P02545 2/20 0.36
PPARG P37231 1/20 0.36
PPARA Q07869 1/20 0.36
GNRHR P30968 3/20 0.35
BCHE P06276 3/20 0.35
TP53 P04637 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
HSD17B10 Q99714 1/20 0.34
MAPT P10636 1/20 0.34
CNR2 P34972 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL648089 0.93 C5AR1 (0.47) C5AR1NPSR1CYP1A2CYP2D6CYP2C9
SCHEMBL5136217 0.92 C5AR1 (0.45) C5AR1NPSR1TSHRKDM4EALDH1A1
SCHEMBL650473 0.91 C5AR1 (0.41) C5AR1NPSR1CYP1A2CYP2D6CYP2C9
SCHEMBL5135620 0.91 C5AR1 (0.43) C5AR1NPSR1TSHRKDM4EALDH1A1
SCHEMBL5136898 0.90 C5AR1 (0.43) C5AR1NPSR1TSHRKDM4EALDH1A1
SCHEMBL651365 0.89 C5AR1 (0.46) C5AR1NPSR1TSHRKDM4EALDH1A1
SCHEMBL5136054 0.89 C5AR1 (0.42) C5AR1NPSR1TSHRKDM4EALDH1A1
SCHEMBL5170483 0.89 C5AR1 (0.45) C5AR1NPSR1TSHRKDM4EALDH1A1
SCHEMBL648706 0.89 C5AR1 (0.46) C5AR1NPSR1CYP1A2CYP2D6CYP2C9
SCHEMBL5137707 0.89 C5AR1 (0.43) C5AR1NPSR1TSHRKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed